Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jun;14(6):1102-1108.
doi: 10.1016/j.jtho.2019.02.026. Epub 2019 Mar 7.

Immune Checkpoint Inhibitor-Associated Pericarditis

Affiliations
Case Reports

Immune Checkpoint Inhibitor-Associated Pericarditis

Mehmet Altan et al. J Thorac Oncol. 2019 Jun.

Abstract

Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor-mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events.

Keywords: Immune-related adverse events; NSCLC; Pericarditis.

PubMed Disclaimer

Conflict of interest statement

Relevant Conflicts of Interest: M.A. has received research funding (to institution) from BMS and Eli Lilly. S.N.G. has received research funding (to institution) from BMS, Nektar, lovance, Genentech, Takeda/ARIAD and is a consultant/advisor to BMS and Nektar. R.S.H. has received honoraria from for following: Consulting: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bristol-Myers Squibb , Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Heat Biologics, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Tesaro, Tocagen. Advisory Boards: Neon Therapeutics, Infinity Pharmaceuticals, NextCure. Research support: AstraZeneca, Eli Lilly and Company, Merck and Company. He is a member of the board of directors (non-executive/ independent) for Junshi Pharmaceuticals. D.L.R. is a consultant / advisor to Astra Zeneca, Agendia, Agilent, Bethyl Labs, Biocept, BMS, Cell Signaling Technology, Cepheid, Merck, OptraScan, Perkin Elmer, and Ultivue. Holds equity in PixelGear. Astra Zeneca, Cepheid, Navigate/Novartis, Gilead Sciences, Ultivue, and Perkin Elmer funds research in Rimm’s lab. All other authors declare no competing interests.

Figures

Figure 1.
Figure 1.
A) Radiation fields for palliative right hilum radiation; 1.B and 1.C) Imaging studies by positron emission tomography, B) Pretreatment and C) after 4 cycle of therapy, with marked clinical response, for case #1
Figure 2.
Figure 2.
A) Fibrinous pericarditis adherent to the parietal (reflected superiorly) and visceral pericardium, 2.B) Bread-loaf sections of the formalin-fixed heart showing a fibrinous, hemorrhagic exudate covering the heart and epicardial fat (green arrow). The epicardial surface is covered by a fibrinous exudate measuring 4-5mm in thickness, representing a classic “bread and butter” pericarditis.
Figure 3:
Figure 3:
1st, 2nd and 3 rd row are macroscopic, H&E and TILs multiplexing images from case 1, 2 and 3 respectively. First column (3.A, 3.F) shows macroscopic images from pericardial sample for case 1, 2; Second column (3.B, 3.G and 3.K) shows H&E images of the pericardial samples x10 magnification), 3rd column (3.C, 3.H and 3.L) is representing multiplexing with CD 3 (green), granzyme (red) and Ki 67 (blue channel); 4th column (3.D, 3.I, 3.M)is representing multiplexing with CD4 (green), CD8 (red), CD20 (blue); 5th column (3.E, 3.J, 3.N) is representing CD68 (green), PD-L1 (red).

References

    1. Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ case reports. 2016;2016. - PMC - PubMed
    1. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. Journal for immunotherapy of cancer. 2015;3(1):11. - PMC - PubMed
    1. Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. The oncologist. 2018;23(8):874–878. - PMC - PubMed
    1. Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation. 2017;136(21):2085–2087. - PubMed
    1. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncology. 2018. - PMC - PubMed

Publication types

Substances